Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Spire Wealth Management

Spire Wealth Management reduced its stake in Illumina, Inc. (NASDAQ:ILMNFree Report) by 34.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 648 shares of the life sciences company’s stock after selling 336 shares during the period. Spire Wealth Management’s holdings in Illumina were worth $89,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. State of Wyoming purchased a new position in shares of Illumina in the 2nd quarter valued at approximately $32,000. Quent Capital LLC boosted its stake in shares of Illumina by 71.2% in the third quarter. Quent Capital LLC now owns 250 shares of the life sciences company’s stock valued at $34,000 after buying an additional 104 shares in the last quarter. ST Germain D J Co. Inc. purchased a new stake in shares of Illumina in the second quarter valued at approximately $36,000. Riverview Trust Co boosted its stake in shares of Illumina by 203.5% in the third quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after buying an additional 175 shares in the last quarter. Finally, WFA of San Diego LLC purchased a new stake in shares of Illumina in the second quarter valued at approximately $37,000. 92.17% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Illumina stock opened at $137.84 on Monday. The firm has a market capitalization of $21.89 billion, a P/E ratio of -18.78, a PEG ratio of 24.83 and a beta of 1.22. The stock has a fifty day moving average price of $135.24 and a 200 day moving average price of $137.59. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $238.55. The company has a current ratio of 1.69, a quick ratio of 1.28 and a debt-to-equity ratio of 0.25.

Illumina (NASDAQ:ILMNGet Free Report) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.15% and a negative net margin of 25.78%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post 1.03 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of analyst reports. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Wolfe Research initiated coverage on Illumina in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $175.00 price target on the stock. Stephens initiated coverage on Illumina in a research note on Thursday, December 14th. They issued an “overweight” rating and a $170.00 price target on the stock. Guggenheim initiated coverage on Illumina in a research note on Thursday, December 14th. They issued a “buy” rating and a $155.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $258.00 price objective on shares of Illumina in a report on Friday. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $166.95.

Check Out Our Latest Stock Report on Illumina

About Illumina

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Articles

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.